Related Experiment Video
Updated: May 6, 2026
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
Published on: May 24, 2024
Sorafenib tosylate as a radiosensitizer in malignant astrocytoma
Jonathan H Sherman1, Jared Kirzner2, Alan Siu1
1Department of Neurosurgery, The George Washington University, 2150 Pennsylvania Avenue, NW, Suite 7-420, Washington, DC 20037, USA.
Abstract:
Progress in research on the molecular aspects of glioblastoma has yet to provide a medical therapy that significantly improves prognosis. Glioblastoma invariably progress through current treatment regimens with radiotherapy as a key component. Activation of several signaling pathways is thought to be associated with this resistance to radiotherapy. Ras activity is exceptionally high in glioblastoma and may regulate sensitivity to radiotherapy. Raf-1, a downstream effector of Ras, demonstrates a high amount of activity in glioblastoma. Therefore, Raf-1 inhibition should be considered as a mechanism to increase the effectiveness of radiotherapy in treatment regimen. In vitro analysis was performed with a novel Raf-1 kinase inhibitor (BAY 54-9085) in culture with the glioblastoma cell line U1242. The cell line was treated in serum-containing media and analyzed for the effect of the BAY 54-9085 alone and BAY 54-9085 combined with radiation on cell death. BAY 54-9085 displayed a cytocidal effect on glioblastoma cells following a 3 day incubation with the drug in serum-containing media. A dose of 2.5 μM displayed moderate cell death which significantly increased with a dose of 5.0 μM. In addition, glioblastoma cells treated with both the BAY 54-9085 and gamma radiation displayed a significant increase in cell death (85.5%) as compared to either BAY 54-9085 (73.1%) or radiation (34.4%) alone. Radiation therapy is a key component of treatment for glioblastoma. A novel Raf-1 inhibitor displayed in vitro evidence of synergistically increasing cell death of glioblastoma cells in combination with radiation.
Insights
A novel Raf-1 inhibitor, BAY 54-9085, shows promise in enhancing glioblastoma treatment. Combining this inhibitor with radiation therapy significantly increased cancer cell death in vitro, suggesting a potential new strategy for improving glioblastoma prognosis.
Area of Science:
- Oncology
- Molecular Biology
- Radiotherapy Research
Background:
- Glioblastoma treatment remains challenging, with limited therapeutic options and poor prognosis despite current regimens.
- Radiotherapy is a cornerstone of glioblastoma treatment, but resistance often develops.
- Aberrant signaling pathways, particularly high Ras activity and downstream Raf-1 activation, are implicated in glioblastoma radioresistance.
Purpose of the Study:
- To investigate the potential of inhibiting Raf-1 kinase to enhance radiotherapy effectiveness in glioblastoma.
- To evaluate the in vitro efficacy of a novel Raf-1 inhibitor, BAY 54-9085, alone and in combination with radiation therapy.
Main Methods:
- In vitro analysis of the U1242 glioblastoma cell line.
- Treatment with BAY 54-9085 at varying concentrations (2.5 μM and 5.0 μM) in serum-containing media.
- Assessment of cell death following treatment with BAY 54-9085 alone and in combination with gamma radiation.
Main Results:
- BAY 54-9085 demonstrated a dose-dependent cytocidal effect on glioblastoma cells.
- A concentration of 5.0 μM BAY 54-9085 resulted in significantly increased cell death compared to 2.5 μM.
- Combination therapy of BAY 54-9085 (5.0 μM) and gamma radiation led to a substantial increase in cell death (85.5%) compared to either treatment alone (BAY 54-9085: 73.1%; radiation: 34.4%).
Conclusions:
- BAY 54-9085 exhibits significant in vitro anti-cancer activity against glioblastoma cells.
- The novel Raf-1 inhibitor BAY 54-9085 synergistically enhances cell death when combined with radiation therapy.
- Targeting Raf-1 represents a promising strategy to overcome radioresistance and improve glioblastoma treatment outcomes.
More Related Videos
06:15Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
11:09Establishing Intracranial Brain Tumor Xenografts With Subsequent Analysis of Tumor Growth and Response to Therapy using Bioluminescence Imaging
Published on: July 13, 2010